Rodman & Renshaw is out with a research report this afternoon, where it reiterates its Outperform rating on Agenus Inc. AGEN; it has a $2.00 price target on the stock.
The R&R analysts cited the company's recent ASCO data, which updated survival results from an ongoing Phase 2 trial evaluating Prophage G-200, a patient-specific heat shock protein-based therapeutic vaccine, for the treatment of recurrent high-grade gliomas.
As for valuation, the analysts remarked, “We are reiterating our Market Outperform / Speculative Risk rating on Agenus with a 12-month target price of $2, based on a comparable company analysis to value the oncology programs in combination with a net present value analysis for the potential contribution of future QS-21 royalty revenue to the company's valuation.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in